Kornimate/medical-research-clean huggingface dataset:
magnitude of osteoarthritis disadvantage on peoples lives

Conditions: Osteoarthritis

Summary: estimate the prevalence of self-reported osteoarthritis and its characterization in adults over 45 years of age: * characterization of self-reported patients with oa (socio-demographic, comorbidities, vas for intensity of pain) * characterization of oa diagnosis in patients with self-reported oa * impact of self-reported oa in the working abilities, quality of life and functionality (sf-12 v2.0) * characterization of treatment approaches (therapeutic and non-therapeutic) for self-reported patients with oa * patient perception of impact of oa in its life and importance given to disease

magnitude of osteoarthritis disadvantage on peoples lives.

Eligibility criteria:
inclusion criteria: - adults over 45 years old with self-reported osteoarthritis exclusion criteria: - na

Keywords: osteoarthritis symptoms
effects of water-based exercise in women with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the objective of the present study was to compare the neuromuscular, cardiorespiratory and metabolic effects of 12 weeks of aerobic training, strength training and combined training in the aquatic environment in women with ms. for this purpose, 51 postmenopausal, sedentary and ms women were randomly divided into three intervention groups: hydro-aerobic (ha, n = 18, 63.77 ± 5.03 years), hydro-power (hf, n = 16, 61.01 ± 4.93 years) and hydro-combined (hc; n = 17; 60.52 ± 6.91). a subsample participated in eight weeks without physical exercise to characterize a control period. the three intervention groups performed two weekly sessions of 60 minutes for 12 weeks. before and after the training period, blood tests, muscle strength tests, cardiorespiratory evaluation, functional tests and a questionnaire were performed. for statistical analysis, the generalized estimates equations (gee) model was used, using the "group" and the "time" as factors. the bonferroni post hoc was used to locate the differences and the significance index adopted was α = 0.05.

water-based exercise as a mode of aquatic exercise has been highlighted in the scientific literature. research on different models of training, aerobic, muscle strength and combined (aerobic and muscle strength), have already demonstrated their beneficial effects on different physical abilities. recent studies indicate benefits of water-based exercise for the population with metabolic diseases such as hypertension, type 2 diabetes, dyslipidemias and obesity. however, for subjects with metabolic syndrome (ms) there are few studies that investigated which training model in the aquatic environment could generate physical and metabolic improvements. this study is characterized as a randomized clinical trial, which treated three intervention groups with physical exercise programs. a subsample participated in a period of eight weeks without physical exercise to characterize a control period. the subjects in this subsample were later randomized into the intervention groups.

Eligibility criteria:
inclusion criteria: * postmenopausal; * sedentary; * presented at least three positive components within the five possible to characterize the metabolic syndrome. exclusion criteria: * smokers.

Keywords: water-base exercise
drug resistance factors in healthcare-associated pneumonia

Conditions: Pneumonia; Critical Illness

Summary: recently clinical guidelines categorize pneumonia in to three types: community, healthcare-associated, and hospital-acquired. much of the existing research to describe the epidemiology of pneumonia in critically ill patients comes from single-center studies or from retrospective database analyses, which limit generalizability and lead to over-prescription of broad-spectrum antibacterial agents. this will be a prospective, multicenter epidemiological study to characterize pneumonia epidemiology in critically ill adult patients.

pneumonia is one of the leading causes of death in the united states and is associated with significant costs to the healthcare system. recent treatment guidelines describe a new subtype of pneumonia, healthcare-associated pneumonia (hcap), to identify those patients who present to a hospital from the community and are thought to be at greater risk for developing pneumonia due to multidrug resistant organisms (mdro). the hcap categorization scheme is intended to improve the prescription of initial appropriate empiric antibacterial agents and minimize the morbidity and mortality associated with inappropriate empiric selection.however, one of the chief criticisms of the guideline recommendations is that the criteria used to define hcap is overly broad, which may result in greater use of broad-spectrum antibiotics. the prevailing notion is that many patients in the community will be at the lowest risk for experiencing mdr pneumonia and can be treated with a less broad anti-infective regimen. patients with increasing exposure to the healthcare system will receive initial anti-infective therapy that is more broad in an effort to target mdros. the investigator group believes that it is not simply exposure to the healthcare system that predicts the incidence of mdr pneumonia (i.e., criteria for hcap), but rather, the "intensity" of exposure to the healthcare system that is predictive of mdr pneumonia. the aim of this study is to identify risk factors for mdr hcap pneumonia in critically ill patients. .

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * icu admission * empiric or directed anti-infective treatment for pneumonia for ≥ 5 days exclusion criteria: * patient stay in icu for \< 24 hours * patient transfer to the icu from a hospital floor following prescription for anti-infective therapy in the previous 24 hours of icu admission * diagnosis of cystic fibrosis or bronchiectasis * fungal pneumonia
safety and efficacy associated with treating erectile dysfunction patients with low intensity shockwaves by renova

Conditions: Vasculogenic Erectile Dysfunction

Summary: this is a prospective, randomized, double-blind clinical study comparing safety and efficacy of the treatments performed with the low intensity extracorporeal shockwave therapy (li-eswt) device - "renova" on symptomatic ed patients to the safety and efficacy of the control sham patients.


Eligibility criteria:
inclusion criteria: * good general health * vascular ed for at least 6 months * international index of erectile function 6 (iief-ef) between 11 to 25 * positive response to pde5-i (able to penetrate on demand=responders) * negative response to pde5-i (unable to penetrate on demand even with maximum pde5-i dosage = non-responders) * stable heterosexual relationship for more than 3 months exclusion criteria: * hormonal, neurological or psychological pathology * past radical prostatectomy or extensive pelvic surgery * recovering from cancer during last 5 years * any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities * clinically significant chronic hematological disease * anti-androgens, oral or injectable androgens * past radiotherapy treatment of the pelvic region * international normalized ratio (inr) \> 3 for patients using blood thinners (such as coumadin)

Keywords: erectile dysfunction extracorporeal shockwave low intensity shockwaves
a dose escalation study of apr003 in patients with advanced colorectal cancer (crc) with malignant liver lesions

Conditions: Advanced Colorectal Carcinoma

Summary: a phase 1 dose escalation study to evaluate apr003 in patients with advanced colorectal cancer (crc) with malignant liver lesions

apr003 is a small molecule tlr7 agonist that concentrates in the gi, and liver with limited systemic exposure. it is designed to increase the therapeutic window of a tlr7 agonist by minimizing the side-effects associated with generalized systemic immune activation and inflammation.

Eligibility criteria:
inclusion criteria: * ecog performance status of 0 or 1 * must have disease that is considered non-surgically resectable. * relapsed or persistent/refractory to at least two prior systemic treatment regimens for locally advanced or metastatic disease considered to be standard-of-care (soc). * must have previously received an irinotecan or oxaliplatin-based therapy, as well as a targeted antibody therapy for metastatic disease * tumors that are msi-h/dmmr must have previously received checkpoint inhibitor therapy * adequate hepatic function * adequate renal function * normal coagulation panel * willingness to use effective contraception exclusion criteria: * current or history of cns metastases * significant cardiovascular disease * pregnant or breastfeeding
influence of g-csf and epo on associative learning and motor skills

Conditions: Chronic Stroke; Amyotrophic Lateral Sclerosis

Summary: in the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (g-csf) and erythropoetin (epo) influence associative learning and/or motor skills of patients, who suffer from chronic stroke or amyotrophic lateral sclerosis. the study hypothesis is that g-csf and epo improve associative learning and/or motor skills.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic stroke or amyotrophic lateral sclerosis exclusion criteria: * leucocytes \> 10000/µl * hematocrit \> 48% * thrombocytes \< 150000/µl * severe rheumatoid arthritis * severe infection * severe liver or renal failure * severe arterial hypertension * recurrent thromboembolic events * severe coronary heart disease * myocardial infarction * malignant tumor * leukemia * peripheral arterial occlusion disease
minoxidil 2% solution and botanical hair regimen in women with thinning hair and female pattern hair loss/androgenic alopecia

Conditions: Female Pattern Hair Loss, Androgenic Alopecia

Summary: the purpose of this study is to characterize the effect of minoxidil 2% solution and botanical hair solution regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (ludwig i and ii).


Eligibility criteria:
key inclusion criteria: 1. female patients age 18 to 60 years at the time of enrollment. 2. women who have self-perceived thinning hair. 3. women who have presentation of female pattern hair loss/androgenic alopecia (ludwig i and ii). key exclusion criteria: 1. history of allergic reactions or severe intolerance to minoxidil and botanical hair solution product ingredients. 2. plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study. 3 subjects taking or planning to take topical or systemic prescription or otc medications for treating hair loss and/or hair volume. 4. any significant history of concurrent medical disease, which in the judgment of the investigator, would make the subject inappropriate for entry to this study including history of skin disease that may confound study results. 5. subjects who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (hrt). women currently using hormones for birth control or hrt must have been on a stable dose (6 months or longer) in order to be eligible for the study. 6. pregnant or breast-feeding females or women planning to become pregnant during the course of the study
the survey of satisfaction in chinese rheumatologists and patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Satisfaction

Summary: a questionnaire for this research is designed, which initiated from tsqm-ii treatment satisfaction questionnaire and based on research launched by rheumatology and immunology departments of chinese 12 public tertiary hospitals distributed directionally by chinese rheumatism data center (crdc). the research is about treatment satisfaction and its influencing factors for chinese rheumatoid immunologists and rheumatoid arthritis (ra) patients as well as their expectations for treating this disease. this research will explore the matching degree between treatment satisfaction and expectation about rheumatoid arthritis from doctors and patients.

in the last decade, china has made quick progress on treatment of rheumatoid arthritis. however, the improvement of remission rate cannot fully represent needs of patients for health. to meet health demands of patients and improve their satisfaction, an efficacy evaluation system based on the outcome report of patients should be established. a questionnaire for this research is designed and mended in view of tsqm-ii treatment satisfaction questionnaire and the actual situation of ra diagnosis and treatment in china. an investigation on treatment satisfaction and its influencing factors for chinese rheumatoid immunologists and rheumatoid arthritis (ra) patients as well as their expectations for this disease is carried out based on 120 rheumatoid immunologists and 1,200 rheumatoid arthritis patients (1:10) from chinese 12 public tertiary hospitals distributed directionally by chinese rheumatism data center (crdc). the research concludes rheumatoid specialist physicians for doctor population, and persons aged over 18 for patient population who has been confirmed as ra for 6 months above, excluding patients with chinese reading comprehension barriers or without any ra treatment. finally, summarize and analyze the total score of satisfaction from doctors and patients, average score of doctors and patients for various medical demands, as well as the satisfaction of patients about communication and service during medical treatment.

Eligibility criteria:
inclusion criteria: doctors - registered rheumatoid specialist physicians subordinated to the 12 designated hospitals patients - aged over 18, confirming ra for more than 6 months exclusion criteria: doctors - n/a patients - with chinese reading comprehension barriers (unable to complete the questionnaire independently), without any ra treatment
a trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with t1dm

Conditions: Hypoglycemia; Diabetes Mellitus, Type 1

Summary: a randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (t1dm)

this multicenter, double-blind, crossover, randomized clinical trial was designed to evaluate the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with t1dm. patients were randomly assigned 1:1 to either dasiglucagon batch a or dasiglucagon batch b as their initial dose and the other as the second dose. to avoid bias in the evaluation of clinical assessments, the trial was conducted in a double-blinded manner.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus for at least 1 year according to the diagnostic criteria as defined by the american diabetes association. * hemoglobin a1c \<10.0% at screening * treated with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening exclusion criteria: * history of hypoglycemic events associated with seizures in the last year prior to screening * history of severe hypoglycemia (an episode requiring assistance from another person) in the last month prior to screening * previous participation in a clinical trial within the dasiglucagon program

Keywords: glucagon
sleepiness in parkinson's patients with continuous dopaminergic delivery device or deep brain stimulation

Conditions: Parkinson Disease

Summary: sleepiness is frequent in parkinsonian patients, increasing with the duration of disease. by patients with motor fluctuations, continuous dopaminergic delivery devices or deep brain stimulation are justified to improve the motor prognosis. antiparkinsonian treatments, especially dopaminergic agonists, may worsen the sleepiness and thus affect the quality of life. the investigators aimed to monitor sleepiness in parkinsonian patients before and during treatment with continous dopaminergic delivery device or deep brain stimulation.


Eligibility criteria:
inclusion criteria: * patient with parkinson's disease and motor fluctuations * and indicated for a continuous dopaminergic delivery device or deep brain stimulation exclusion criteria: * age \< 18 years * refusal for the continuous dopaminergic delivery device or deep brain stimulation * wake-promoting drugs intake * refusal to participate * legal protection * uncontrolled sleep apnea

Keywords: continous dopaminergic delivery device deep brain stimulation sleepiness
proparacaine vs placebo for corneal injuries

Conditions: Corneal Abrasions

Summary: introduction: traumatic injuries to the outer covering of the eye (the cornea) are a common emergency department complaint. they cause significant patient distress including pain, loss of sleep and missed work days. there is currently no accepted, uniform approach to pain management in this patient population. emergency medicine and ophthalmology texts state that prolonged use of medications that anesthetize the cornea is not recommended. several recent publications in the ophthalmology literature show that the outpatient use of dilute local anesthesia in patients after eye surgery is a safe and effective method of pain control. in this study, we used proparacaine (a local anesthetic), in a similar manner, for the outpatient emergency department management of traumatic corneal injuries. methods: we performed a clinical trial on a sample of adult patients presenting with traumatic corneal injuries to two university affiliated emergency departments in london, canada. patients providing signed informed consent to participate in the study received a vial of clear liquid that contained either proparacaine or plain water (placebo), a pain log, topical antibiotics and oral acetaminophen (tylenol) with codeine for breakthrough pain. patients were instructed to use the "study drug" on an "as-needed" basis for the next seven days. patients completed a pain scale describing their discomfort immediately prior to, and five minutes after self-administration of the study drug. all patients were followed closely in an ophthalmology outpatient clinic on days 1, 3 and 5 after presentation to the emergency department. at the last ophthalmology clinic visit, the patients' pain logs were collected. the protocol was approved by the research ethics board for health sciences research involving human subjects at the university of western ontario.


Eligibility criteria:
inclusion criteria: * adult patients with acute (within 24 hrs) traumatic corneal injuries exclusion criteria: * immunocompromised * known allergy to local anesthetic * unable to consent /follow instructions for dosing / go to follow-up appointments * previous ocular pathology

Keywords: cornea analgesia topical anesthetic
eswl versus sopil for treatment of pancreatic duct stones

Conditions: Chronic Pancreatitis; Pancreatic Duct Stone

Summary: pancreatic duct stones can cause obstruction of the main pancreatic duct leading to abdominal pain, exocrine pancreatic insufficiency, and recurrent acute pancreatitis. by removing pancreatic duct stones, the obstruction can be relieved, and this can improve symptoms. small stones can be removed with standard endoscopic retrograde cholangiopancreatography (ercp) and stone removal, but larger stones may require lithotripsy to break up the stone before removal. the two current methods of lithotripsy include extracorporeal shock wave lithotripsy (eswl) and single operator pancreatoscopy with intracorporeal lithotripsy (sopil). eswl is based on concentrating shock wave energy to the stone through an external device. sopil is a newer technique based on direct visualization of the stone during ercp and targeting the stone with a shock wave catheter. there are currently no studies directly comparing eswl to sopil for breaking apart stones in the pancreatic duct, so this study is designed to compare the two techniques. objective #1: obtain pilot data to determine the optimal method of clearing large mpds objective #2: obtain pilot data to assess how effective large mpds clearance is in improving long term patient centered outcomes objective #3: obtain pilot data to measure the cost effectiveness of large mpds clearance


Eligibility criteria:
inclusion criteria: * mpds located in the head, neck, or neck/body junction of the pancreas * mpds \> 5 mm in size * abdominal ct scan, endoscopic ultrasound, or prior ercp demonstrating mpds * abdominal pain related to mpds * previously failed ercp performed with intent to clear mpds, or mpds determined by treating physicians to not be amenable to clearance by standard ercp techniques exclusion criteria: * mpds predominantly located in the body and tail of pancreas * any obstructing mpds \> 5 mm located in the body and tail of pancreas * known pancreatic head stricture precluding passage of the pancreatoscope with endoscopic stone extraction based on prior imaging or prior ercp * pancreatic head mass * impacted mpds located at the pancreatic duct orifice * prior attempts at eswl or sopil for mpds * walled off pancreatic necrosis * active alcohol use, defined as any alcohol use within 2 months * surgically altered anatomy (see text) * gastric outlet obstruction or obstruction precluding passage of the endoscope * standard contraindications to ercp * implanted cardiac pacemakers or defibrillators * known calcified aneurysms in the path of the shockwave * age \< 18 years, pregnancy, incarceration, unwillingness/inability to provide informed consent, or anticipated inability to follow protocol

Keywords: extracorporeal shock wave lithotripsy intraductal lithotripsy
pre-eclampsia and biochemical markers

Conditions: Detection of Preeclampsia Complications

Summary: in view of both endothelial injury in pre-eclampsia, high blood pressure and kidney impairment characteristics, a recent study demonstrated that the serum levels of ngal increased at the end of the second trimester in women who subsequently developed pre-eclampsia compared to the control group. this correlates well with the endothelial damage that occurs during pre-eclampsia and thus ngal can be considered as a promising marker in predicting both early and late onset pre-eclampsia. it may be required to combine one or more biomarker with ngal to increase the precision, and sensitivity for detection of risk and reliability of using biomarkers for pre-eclampsia.


Eligibility criteria:
inclusion criteria: * age 20-40 years. * gestational age \>20 weeks. exclusion criteria: * patients with preexisting renal disease,hypertension, diabetes mellitus, gestational hypertension. * patients refuse to participate in the study * patients already have complicated preeclampsia.